Alpha-1-antitrypsin subcutaneous - Intrexon

Drug Profile

Alpha-1-antitrypsin subcutaneous - Intrexon

Alternative Names: recombinant human alpha-1-antitrypsin - Intrexon; rHuA1AT - Intrexon

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intrexon Corporation
  • Class Acute-phase proteins; Alpha globulins; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Alpha 1-antitrypsin deficiency

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alpha-1-antitrypsin-deficiency in USA (SC, Injection)
  • 06 Jun 2011 Preclinical trials in Alpha 1-antitrypsin deficiency in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top